What type of study is this?

September 18, 2025Liver InternationalOpen Access

Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial

View Full Paper

Ask AI

Bookmark

Authors

YZYanting ZouGuangzhou Experimental Station SWSzu‐Yuan WuFu Jen Catholic University WZWanqin ZhangSun Yat-sen University

Discussion

Member takes

Implication

Randomised trial showed fucoidan improved disease control rate and preserved liver function in patients with unresectable HCC, suggesting beneficial synergy with TACE.

Key Points

Fucoidan improved disease control rate significantly, demonstrating 95.24% in the treatment group compared to 80.00% in the placebo group.
Patients receiving fucoidan maintained better liver function, with 80.95% sustaining Child-Pugh Class A status versus 62.50%.
This double-blind, placebo-controlled trial involved 82 patients with unresectable HCC undergoing TACE alongside fucoidan.
The findings highlight the potential of fucoidan to enhance treatment outcomes in unresectable HCC while having a favourable safety profile.

Cite This Study

Zou et al. (2025) studied this question.

synapsesocial.com/papers/68d461cb31b076d99fa613fc https://doi.org/10.1111/liv.70347

View Full Paper

Ask AI

Bookmark

Implication

Randomised trial showed fucoidan improved disease control rate and preserved liver function in patients with unresectable HCC, suggesting beneficial synergy with TACE.

Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider